Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Merck KGaA, Darmstadt, Germany
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
First-line mCRC
EGFR positive
Bi-dimensional measurable index lesion
You may not be if
Previous exposure to EGFR-targeting therapy
Previous oxaliplatin-based therapy
Previous chemotherapy for colorectal cancer except adjuvant treatment with progression of disease documented \> 6 months after end of adjuvant treatment
Radiotherapy
Surgery
Any other investigational drug in the 30 days before randomization
Brain metastasis and/or leptomeningeal disease
Acute or sub-acute intestinal occlusion or history of inflammatory bowel disease
Clareo Health | Oxaliplatin and Cetuximab in First-line Treatment of Metastatic Colorectal Cancer (mCRC)
